Medicine care team

Education:

• MD, 1989, Boston University, U.S.
• FRCPC, 1996, internal medicine, University of Toronto, Canada
• FRCPC, 1997, hematology, U of T
• Fellowship, 1999, lymphoma, Odette Cancer Centre
• Diploma, 2002, clinical epidemiology, U of T

Appointments and Affiliations:

• Affiliate scientist, Biological Sciences, Odette Cancer Research Program, Sunnybrook Research Institute
• Hematologist, medical oncology and hematology, Odette Cancer Centre, Sunnybrook Health Sciences Centre
• Associate professor, department of medicine, U of T
• Head, hematology site group, Odette Cancer Centre
• Director, myelodysplastic syndrome (MDS) research program, Odette Cancer Centre
• Director, Canadian National Myelodysplastic Syndromes Registry

Research Foci:

• Novel biologic therapies for hematological malignancies
• Myelodysplastic syndromes (MDS)
• Lymphomas
• Impact of patient-related factors on clinical and patient-reported outcomes in MDS
• Factors that impact quality of life in MDS

Research Summary:

Dr. Buckstein's research is clinical and focused on novel biological therapies for MDS and lymphomas. She is a clinician-investigator and interacts closely with the scientists of Sunnybrook Research Institute and elsewhere on collaborative projects. She conducts investigator-initiated research in the following areas:

• targeted therapy and immunotherapy
• red blood cell transfusions in MDS
• MDS mutations as a component of aging
• health outcomes research
• patient reported outcomes
• frailty and comorbidity as prognostic factors.

Dr. Buckstein is supported by research funding from the Canadian Institutes of Health Research and Canadian Cancer Society Research Institute.

Selected Publications:

See current publications list at PubMed.

Related News and Stories:

• Research into cancer technologies and services recognized with funding: Six Sunnybrook Research Institute scientists working in prevention, screening and care receive support from provincial network (June 4, 2019)
• Studies help blood cancer patients make treatment decisions: New risk score is more comprehensive than previous one, and only chemotherapy in early-stage disease a viable option for some (SRI Magazine, 2016)